{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:53:13Z","timestamp":1772761993796,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T00:00:00Z","timestamp":1508889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006667","name":"Ministerio de Educaci\u00f3n de la Naci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003425","name":"Departamento de Educaci\u00f3n, Gobierno de Navarra","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of preemptive antiviral therapy to prevent cytomegalovirus (<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>) disease in allogeneic hematopoietic stem cell transplantation (allo\u2010<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>) recipients might result in over\u2010treatment, inducing drug\u2010related toxicity and viral resistance. A search for predictive markers is needed to determine requirement for antiviral therapy. Clinical follow\u2010up, in combination with the use of streptamers (<jats:styled-content style=\"fixed-case\">ST<\/jats:styled-content>s) and cytokine\u2010intracellular staining, could help to identify patients at high risk for <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> reactivations. To study the immune response and reactivation control by <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>\u2010specific <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>8<jats:sup>+<\/jats:sup> T\u2010cell (<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CTL<\/jats:styled-content>) populations, we monitored 25 patients who have undergone allo\u2010<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> by using <jats:styled-content style=\"fixed-case\">ST<\/jats:styled-content> multimer and intracellular cytokine staining. Our study has revealed that the presence of functional <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>\u2010specific T cells, determined by early interferon \u03b3 production or by significant T\u2010cell expansion after first <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> reactivation, correlated with short <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> viremia duration and low number of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> reactivations. By contrast, the absence of functional <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CTLs<\/jats:styled-content> does correlate with <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> recurrence. These results support that behavior of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>\u2010specific subpopulations after reactivation influences reactivations and can guide preemptive therapy.<\/jats:p>","DOI":"10.1111\/tid.12778","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T14:10:25Z","timestamp":1505743825000},"source":"Crossref","is-referenced-by-count":14,"title":["Functional specific\u2010T\u2010cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients"],"prefix":"10.1111","volume":"19","author":[{"given":"Miriam","family":"Ci\u00e1urriz","sequence":"first","affiliation":[{"name":"Oncohematology Research Group Navarrabiomed\u2010Miguel Servet Foundation IDISNA (Navarra's Health Research Institute)  Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorea","family":"Beloki","sequence":"additional","affiliation":[{"name":"Oncohematology Research Group Navarrabiomed\u2010Miguel Servet Foundation IDISNA (Navarra's Health Research Institute)  Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaya","family":"Zabalza","sequence":"additional","affiliation":[{"name":"Oncohematology Research Group Navarrabiomed\u2010Miguel Servet Foundation IDISNA (Navarra's Health Research Institute)  Pamplona Spain"},{"name":"Department of Haematology Complejo Hospitalario de Navarra Navarra Health Service IDISNA  Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Bandr\u00e9s","sequence":"additional","affiliation":[{"name":"Oncohematology Research Group Navarrabiomed\u2010Miguel Servet Foundation IDISNA (Navarra's Health Research Institute)  Pamplona Spain"},{"name":"Department of Haematology Complejo Hospitalario de Navarra Navarra Health Service IDISNA  Pamplona Spain"},{"name":"Immunology Unit Complejo Hospitalario de Navarra Navarra Health Service IDISNA  Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mansilla","sequence":"additional","affiliation":[{"name":"Oncohematology Research Group Navarrabiomed\u2010Miguel Servet Foundation IDISNA (Navarra's Health Research Institute)  Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estela","family":"P\u00e9rez\u2010Valderrama","sequence":"additional","affiliation":[{"name":"Oncohematology Research Group Navarrabiomed\u2010Miguel Servet Foundation IDISNA (Navarra's Health Research Institute)  Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Lach\u00e9n","sequence":"additional","affiliation":[{"name":"Oncohematology Research Group Navarrabiomed\u2010Miguel Servet Foundation IDISNA (Navarra's Health Research Institute)  Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Rodr\u00edguez\u2010Calvillo","sequence":"additional","affiliation":[{"name":"Oncohematology Research Group Navarrabiomed\u2010Miguel Servet Foundation IDISNA (Navarra's Health Research Institute)  Pamplona Spain"},{"name":"Department of Haematology Complejo Hospitalario de Navarra Navarra Health Service IDISNA  Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-1053","authenticated-orcid":false,"given":"Natalia","family":"Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Oncohematology Research Group Navarrabiomed\u2010Miguel Servet Foundation IDISNA (Navarra's Health Research Institute)  Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Olavarr\u00eda","sequence":"additional","affiliation":[{"name":"Oncohematology Research Group Navarrabiomed\u2010Miguel Servet Foundation IDISNA (Navarra's Health Research Institute)  Pamplona Spain"},{"name":"Department of Haematology Complejo Hospitalario de Navarra Navarra Health Service IDISNA  Pamplona Spain"},{"name":"Imperial College Healthcare NHS Trust Hammersmith Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,10,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.120"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2005.10.017"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.265"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041648"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21799"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21348"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12391"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21367"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2013.07.014"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705932"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050248"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-631853"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23621"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.261"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.330"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005832"},{"key":"e_1_2_7_18_1","first-page":"e318","article-title":"Characterization of CMV\u2010specific CD4+ T\u2010cell reconstitution following stem cell transplantation through the use of HLA Class II\u2010peptide tetramers identifies patients at high risk of recurrent CMV reactivation","volume":"100","author":"Raeiszadeh M","year":"2015","journal-title":"Haematologica"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401990"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12778","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T03:08:46Z","timestamp":1696043326000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,25]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/tid.12778"],"URL":"https:\/\/doi.org\/10.1111\/tid.12778","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,25]]},"article-number":"e12778"}}